Media Summary: Prof. Caroline Robert (Gustave Roussy, France) presents at ASCO 2017 the results of the KEYNOTE-006 study, showing ... Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on updated results from the Phase III ... Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the

Long Term Efficacy Of Pembrolizumab In Advanced Melanoma - Detailed Analysis & Overview

Prof. Caroline Robert (Gustave Roussy, France) presents at ASCO 2017 the results of the KEYNOTE-006 study, showing ... Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on updated results from the Phase III ... Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the Alexander M. Eggermont, MD, PhD, professor of Oncological Surgery and general director of Gustave Roussy Cancer Campus ... Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Dr Sapna Patel speaks to ecancer about the SWOG S1801 trial which studied the use of neoadjvuant versus adjuvant ...

Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, provides an overview of his highlight of ... Keith Flaherty, MD, and Jeffrey Weber, MD, PhD, discuss data concerning the use of immunotherapy agents, ipilimumab, ... Prof Eggermont speaks with ecancer at AACR 2018 about reducing recurrence of Prof Ribas presents the findings of a phase III trial, which showed This study pools patient cohorts from randomized and nonrandomized Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, ...

Mario Sznol, MD, a professor of medical oncology at the Yale Cancer Center in New Haven, Connecticut, discusses the Jason Luke reports on key results from ESMO Congress 2021 on LBA3 - Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the design and the findings from the ... Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, ... Dr Jorge Nieva speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest ...

Photo Gallery

Long-term efficacy of pembrolizumab in advanced melanoma
KEYNOTE-716: long-term efficacy and safety of pembrolizumab in resected melanoma
KEYNOTE-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
Efficacy of pembrolizumab treatment in mucosal melanoma
3-Year Update Shows Continued Efficacy of Pembrolizumab for Melanoma
Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
TILs prolong PFS compared with pembrolizumab in advanced melanoma
The Phenomenon of Immunotherapy in Melanoma
Reducing recurrence of advanced melanoma with pembrolizumab
Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial
Pembrolizumab, Tumor Response, and Survival in Advanced Melanoma
Sponsored
Sponsored
View Detailed Profile
Long-term efficacy of pembrolizumab in advanced melanoma

Long-term efficacy of pembrolizumab in advanced melanoma

Prof. Caroline Robert (Gustave Roussy, France) presents at ASCO 2017 the results of the KEYNOTE-006 study, showing ...

KEYNOTE-716: long-term efficacy and safety of pembrolizumab in resected melanoma

KEYNOTE-716: long-term efficacy and safety of pembrolizumab in resected melanoma

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on updated results from the Phase III ...

Sponsored
KEYNOTE-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma

KEYNOTE-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma

Georgina

Efficacy of pembrolizumab treatment in mucosal melanoma

Efficacy of pembrolizumab treatment in mucosal melanoma

Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the

3-Year Update Shows Continued Efficacy of Pembrolizumab for Melanoma

3-Year Update Shows Continued Efficacy of Pembrolizumab for Melanoma

Alexander M. Eggermont, MD, PhD, professor of Oncological Surgery and general director of Gustave Roussy Cancer Campus ...

Sponsored
Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel speaks to ecancer about the SWOG S1801 trial which studied the use of neoadjvuant versus adjuvant ...

TILs prolong PFS compared with pembrolizumab in advanced melanoma

TILs prolong PFS compared with pembrolizumab in advanced melanoma

Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, provides an overview of his highlight of ...

The Phenomenon of Immunotherapy in Melanoma

The Phenomenon of Immunotherapy in Melanoma

Keith Flaherty, MD, and Jeffrey Weber, MD, PhD, discuss data concerning the use of immunotherapy agents, ipilimumab, ...

Reducing recurrence of advanced melanoma with pembrolizumab

Reducing recurrence of advanced melanoma with pembrolizumab

Prof Eggermont speaks with ecancer at AACR 2018 about reducing recurrence of

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Prof Ribas presents the findings of a phase III trial, which showed

Pembrolizumab, Tumor Response, and Survival in Advanced Melanoma

Pembrolizumab, Tumor Response, and Survival in Advanced Melanoma

This study pools patient cohorts from randomized and nonrandomized

Dr. Antoni Ribas on the Efficacy of Lambrolizumab in Advanced Melanoma

Dr. Antoni Ribas on the Efficacy of Lambrolizumab in Advanced Melanoma

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, ...

Dr. Mario Sznol Reviews the Efficacy  of Nivolumab in Advanced Melanoma

Dr. Mario Sznol Reviews the Efficacy of Nivolumab in Advanced Melanoma

Mario Sznol, MD, a professor of medical oncology at the Yale Cancer Center in New Haven, Connecticut, discusses the

Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced Melanoma

Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced Melanoma

Georgina V.

KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma

KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma

Ines Pires da Silva, MD, PhD,

#ESMO21 Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study

#ESMO21 Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study

Jason Luke reports on key results from ESMO Congress 2021 on LBA3 -

KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanoma

KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the design and the findings from the ...

Efficacy and Safety Results for Pembrolizumab in Previously Treated Gastric Cancer

Efficacy and Safety Results for Pembrolizumab in Previously Treated Gastric Cancer

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, ...

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest ...